SCHEMBL1168367

SCHEMBL1168367

Nc1nc(Nc2ccccc2)nn1C(=O)c1ccc(N2CCOCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.59
INSR P06213 1/20 0.59
CCNB2 O95067 1/20 0.57
CDK1 P06493 1/20 0.57
CCNB1 P14635 1/20 0.57
CCNB3 Q8WWL7 1/20 0.57
JAK1 P23458 3/20 0.56
TYK2 P29597 3/20 0.56
JAK3 P52333 2/20 0.56
KIT P10721 3/20 0.54
FLT3 P36888 3/20 0.54
JAK2 O60674 3/20 0.52
KDM1A O60341 1/20 0.50
F12 P00748 2/20 0.49
PLK4 O00444 1/20 0.49
LRRK2 Q5S007 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1167567 0.90 JAK1 (0.54) AXLINSRCCNB2CDK1CCNB1
SCHEMBL1167417 0.89 AXL (0.60) AXLINSRCCNB2CDK1CCNB1
SCHEMBL1167740 0.87 AXL (0.57) AXLINSRCCNB2CDK1CCNB1
SCHEMBL1167710 0.87 CDK1 (0.69) AXLINSRCCNB2CDK1CCNB1
SCHEMBL1167094 0.85 AXL (0.55) AXLINSRCCNB2CDK1CCNB1
SCHEMBL1168120 0.84 INSR (0.57) AXLINSRCCNB2CDK1CCNB1
SCHEMBL1167667 0.84 AXL (0.57) AXLINSRCCNB2CDK1CCNB1
SCHEMBL1168002 0.84 AXL (0.55) AXLINSRCCNB2CDK1CCNB1
SCHEMBL1248143 0.83 CCNB2 (0.77) AXLCCNB2CDK1CCNB1CCNB3
SCHEMBL1167499 0.81 CSF1R (0.56) AXLINSRJAK1TYK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389557-B2 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2013-03-05 US disclosed
US-20110082131-A1 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-7884119-B2 protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation RIGEL PHARMACEUTICALS, INC. (US) 2011-02-08 US disclosed
EP-1922310-A2 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2008-05-21 EP disclosed
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2007-09-13 US disclosed
WO-2007030680-A2 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082131-A1 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS AXL, TYRO3, FLT3 AXL 1/4885INSR 508/4885CCNB2 1915/4885
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors AXL, TYRO3, FLT3 AXL 1/4885INSR 291/4885CCNB2 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.